摘要
病理性近视眼指高度近视眼伴眼底病理性改变,继发脉络膜新生血管是其严重并发症之一,也是导致视力下降的主要因素。目前一线治疗方法是抗血管内皮生长因子(VEGF)治疗,具有疗效确定、安全性高、视力预后较好等优势。常用抗VEGF药物包括贝伐单克隆抗体、雷珠单克隆抗体、阿柏西普、康柏西普。主要治疗方案包括1+pro re nata(PRN)和3+PRN,临床多以雷珠单克隆抗体治疗病理性近视眼继发脉络膜新生血管的Ⅱ期临床试验提出的标准对再注射进行评估。本文针对抗VEGF治疗的优势、药物选择、治疗方案及再注射标准,对相关研究进展进行综述,以期为临床治疗提供参考。
Pathological myopia refers to high myopia with fundus pathological changes.Choroidal neovascularization is one of its serious complications,and also the main cause of visual loss.Currently,the first-line treatment is anti-VEGF treatment,with good efficacy,high safety,good prognosis,and other advantages of vision.Commonly used anti-VEGF drugs include bevacizumab,ranibizumab,aflibercept,and conbercept.The main treatment strategies include 1+pro re nata and 3+pro re nata,and the standard of REPAIR test is often used to evaluate the re-injection.This article reviews the advantages of anti-VEGF therapy,drug selection,treatment strategy,and re-injection criteria.(Chin J Ophthalmol,2019,55:791-795)
作者
史绪晗
魏文斌
Shi Xuhan;Wei Wenbin(Beijing Tongren Eye Center,Beijing Tongren Hospital,Capital Medical University,Beijing Key Laboratory of Ophthalmology&Visual Sciences,Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment,Beijing 100730,China)
出处
《中华眼科杂志》
CAS
CSCD
北大核心
2019年第10期791-795,共5页
Chinese Journal of Ophthalmology
基金
中国科学院战略性科技先导专项项目(XDA01030000)
国家自然科学基金(81570891)
北京市医院管理局"登峰"人才培养计划(DFL20150201)
眼内肿瘤诊治研究北京市重点实验室2015年度科技创新基地培育与发展专项项目(Z151100001615052)
北京市医院管理局临床医学发展专项经费资助(扬帆计划)(ZYLX201307)。
关键词
近视
退行性
脉络膜新生血管化
血管内皮生长因子A
血管生成抑制剂
Myopia
degenerative
Choroidal neovascularization
Vascular endothelial growth factor A
Angiogenesis inhibitors
